EUVIMEDEUVIMED entdecken
Crossref

Discovery of YSR734: A Covalent HDAC Inhibitor with Cellular Activity in Acute Myeloid Leukemia and Duchenne Muscular Dystrophy

Yasir S Raouf, Abootaleb Sedighi iD, Mulu Geletu, Geordon A Frere iD, Rebecca G Allan, Nabanita Nawar, Elvin D de Araujo, Patrick T Gunning iD

Journal of Medicinal Chemistry · 2023

DOI: 10.1021/acs.jmedchem.3c01236 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Yasir S Raouf und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Road, Mississauga, Ontario L5L 1C6, Canada. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Canadian Institutes of Health Research, Canada Foundation for Innovation, Canada Research Chairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Histone deacetylases (HDACs) have emerged as powerful epigenetic modifiers of histone/non-histone proteins via catalyzing the deacetylation of ε-N-acetyl lysines. The dysregulated activity of these Zn2+-dependent hydrolases has been broadly implicated in disease, notably cancer. Clinically, the recurring dose-limiting toxicities of first-generation HDACi sparked a paradigm shift toward safer isoform-specific molecules. With pervasive roles in aggressive diseases, there remains a need for novel approaches to target these enzymes. Herein, we report the discovery of YSR734, a first-in-class covalent HDACi, with a 2-aminobenzanilide Zn2+ chelate and a pentafluorobenzenesulfonamide electrophile. This class I selective proof of concept modified HDAC2Cys274 (catalytic domain), with nM potency against HDAC1-3, sub-μM activity in MV4-11 cells, and limited cytotoxicity in MRC-9 fibroblasts. In C2C12 myoblasts, YSR734 activated muscle-specific biomarkers myogenin/Cav3, causing potent differentiation into myotubes (applications in Duchenne Muscular Dystrophy). Current efforts are focused on improving in vivo ADME toward a preclinical covalent HDACi.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, DuchenneLeukemia, Myeloid, AcuteHumansHistone Deacetylase InhibitorsProtein IsoformsHistone Deacetylases

Substanzen

Histone Deacetylase InhibitorsProtein IsoformsHistone Deacetylases

Autor:innen und Institutionen

  • Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Road, Mississauga, Ontario L5L 1C6, Canada.
  • Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, Ontario M5S 3H6, Canada.

ORCID-Profile: Abootaleb Sedighi, Geordon A Frere, Patrick T Gunning

Förderung

  • Canadian Institutes of Health Research
  • Canada Foundation for Innovation
  • Canada Research Chairs
  • Horizon 2020 Framework Programme
  • Natural Sciences and Engineering Research Council of Canada
  • Leukemia and Lymphoma Society of Canada
  • Canadian Cancer Society
  • Ontario Ministry of Research, Innovation and Science

Zitieren

APA

Raouf, Y. S., Sedighi, A., Geletu, M., Frere, G. A., Allan, R. G., Nawar, N., de Araujo, E. D., & Gunning, P. T. (2023). Discovery of YSR734: A Covalent HDAC Inhibitor with Cellular Activity in Acute Myeloid Leukemia and Duchenne Muscular Dystrophy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01236

Vancouver

Raouf YS, Sedighi A, Geletu M, Frere GA, Allan RG, Nawar N, et al. Discovery of YSR734: A Covalent HDAC Inhibitor with Cellular Activity in Acute Myeloid Leukemia and Duchenne Muscular Dystrophy. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c01236

BibTeX
@article{Raouf2023,
  author = {Raouf, Yasir S and Sedighi, Abootaleb and Geletu, Mulu and Frere, Geordon A and Allan, Rebecca G and Nawar, Nabanita and de Araujo, Elvin D and Gunning, Patrick T},
  title = {Discovery of YSR734: A Covalent HDAC Inhibitor with Cellular Activity in Acute Myeloid Leukemia and Duchenne Muscular Dystrophy},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  doi = {10.1021/acs.jmedchem.3c01236}
}
Kostenlos starten →